Aptose to Report Third Quarter 2022 Financial Results and Hold Conference Call on Tuesday, November 1, 2022

SAN DIEGO and TORONTO, Oct. 18, 2022 -- Aptose Biosciences Inc. , a clinical- stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic... | October 18, 2022

Related Keywords

Toronto ,Ontario ,Canada ,Aptose Biosciences ,Susan Pietropaolo ,Lifesci Advisors ,Aptose Biosciences Inc ,Nasdaq ,Globenewswire Inc ,Webcast Only ,Participant Registration ,Investor Relations ,Sci Advisors ,Managing Director ,Aptose Biosciences Inc Stock Exchange ,News ,Information ,Press Release ,Han ,Iego ,End ,022 ,Aptose ,Iosciences ,Stage ,Precision ,Ncology ,Company ,Developing ,Ighly ,Differentiated ,Mural ,Inase ,Inhibitors ,O ,Reat Aps Ca03835t2002 ,